KRAS Inhibitors Market
完整報告名稱與涵蓋範圍
KRAS Inhibitors Market Size, Share & Trends Analysis Report By Cancer Type (Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Others), By End-Use (Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, Others), By Region, And By Segment Forecasts, 2025-2034
報告摘要
The KRAS Inhibitors Market on a global scale was estimated at USD 476.0 Mn in 2024 and is expected to attain USD 2,916.8 Mn by 2034, with a projected CAGR of 20.0% between 2025 and 2034.
KRAS Inhibitors encompasses challenges.
Several factors contribute to this trajectory, including heightened requirement next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, bolstered by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global KRAS Inhibitors Market Snapshot
Chapter 4. Global KRAS Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Cancer Type Estimates & Trend Analysis
5.1. By Cancer Type, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Cancer Type:
5.2.1. Lung Cancer
5.2.2. Pancreatic Cancer
5.2.3. Colorectal Cancer
5.2.4. Others
Chapter 6. Market Segmentation 2: By End-Use Estimates & Trend Analysis
6.1. By End-Use & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-Use:
6.2.1. Clinic Laboratories
6.2.2. Cancer Diagnostic Centers
6.2.3. Hospitals
6.2.4. Cancer Research Institutes
6.2.5. Academic Institutions
6.2.6. Others
Chapter 7. KRAS Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America KRAS Inhibitors Market revenue (US$ Million) estimates and forecasts By Cancer Type, 2021-2034
7.1.2. North America KRAS Inhibitors Market revenue (US$ Million) estimates and forecasts By End-Use, 2021-2034
7.1.3. North America KRAS Inhibitors Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe KRAS Inhibitors Market revenue (US$ Million) By Cancer Type, 2021-2034
7.2.2. Europe KRAS Inhibitors Market revenue (US$ Million) By End-Use, 2021-2034
7.2.3. Europe KRAS Inhibitors Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific KRAS Inhibitors Market revenue (US$ Million) By Cancer Type, 2021-2034
7.3.2. Asia Pacific KRAS Inhibitors Market revenue (US$ Million) By End-Use, 2021-2034
7.3.3. Asia Pacific KRAS Inhibitors Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America KRAS Inhibitors Market revenue (US$ Million) By Cancer Type, (US$ Million) 2021-2034
7.4.2. Latin America KRAS Inhibitors Market revenue (US$ Million) By End-Use, (US$ Million) 2021-2034
7.4.3. Latin America KRAS Inhibitors Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa KRAS Inhibitors Market revenue (US$ Million) By Cancer Type, (US$ Million) 2021-2034
7.5.2. Middle East & Africa KRAS Inhibitors Market revenue (US$ Million) By End-Use, (US$ Million) 2021-2034
7.5.3. Middle East & Africa KRAS Inhibitors Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Amgen
8.2.2. Boehringer Ingelheim
8.2.3. BridgeBio Pharma
8.2.4. Erasca
8.2.5. Innovent Biologics, Inc.
8.2.6. Incyte
8.2.7. Mirati Therapeutics
8.2.8. Novartis
8.2.9. Jemincare
8.2.10. Cardiff Oncology,Inc.
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們